TNF and inflammatory bowel disease: The most notable difference appears when observing the incidence in patients with IBD, with 126.53 cases/100,000 patients treated with a TNF-α inhibitor, 6 times higher than that found in patients with rheumatic disease and almost 4 times higher than the overall incidence found in the meta-analysis.